2.67
-0.1(-3.61%)
Currency In USD
| Previous Close | 2.77 |
| Open | 2.77 |
| Day High | 2.76 |
| Day Low | 2.56 |
| 52-Week High | 9.79 |
| 52-Week Low | 1.15 |
| Volume | 5.5M |
| Average Volume | 4.61M |
| Market Cap | 414.17M |
| PE | -3.87 |
| EPS | -0.69 |
| Moving Average 50 Days | 1.83 |
| Moving Average 200 Days | 4.06 |
| Change | -0.1 |
If you invested $1000 in Humacyte, Inc. (HUMA) since IPO date, it would be worth $276.11 as of June 01, 2025 at a share price of $2.67. Whereas If you bought $1000 worth of Humacyte, Inc. (HUMA) shares 3 years ago, it would be worth $465.16 as of June 01, 2025 at a share price of $2.67.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq
GlobeNewswire Inc.
May 19, 2025 8:05 PM GMT
DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
GlobeNewswire Inc.
May 09, 2025 12:00 PM GMT
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for
Humacyte to Present Fourth Quarter and Full Year Financial Results and Provide Corporate Update on March 28, 2025
GlobeNewswire Inc.
Mar 26, 2025 12:00 PM GMT
DURHAM, N.C., March 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results f